

Pfizer Quality Improvement RFP

Approaches to Improve Delivery of Quality of Care for Patients with Inflammatory, and Immune Skin Diseases

Competitive Grant Program –Pfizer Internal Review Process



Overview

Through this educational grant, Pfizer is seeking proposals for quality improvement projects aimed at enhancing the medical skills of healthcare professionals, promoting a high-quality healthcare system, and ensuring the delivery of appropriate medical care for patients with Allergic, Inflammatory, and Immune Skin Diseases.



Geographic Scope

Japan



Project Types and Area of Interest

Clinical Area: Allergic, Inflammatory, and Immune Skin Diseases

Objective: The primary objective of this program is to provide support for initiatives that address the unmet medical needs in the treatment of allergic, inflammatory, and immune skin diseases, with a focus on advancing medical systems.



Key Milestones

- Application submission deadline: ~~July 31, 2023~~
Extended Due Date: August 16, 2023
- Anticipated decision notification date: October 31, 2023
- Anticipated project start date: January 1, 2024



Funding Range and Project Length

- Individual projects requesting up to 2,500,000 JPY will be considered.
(Two to several grants will be selected)
- Project execution period: January 1, 2024 - December 31, 2026 (1-3 years)

Note this RFP is also available in [Japanese](#) for your convenience

I. Eligibility

Geographic Scope:

Japan

Applicant Eligibility Criteria

- Only organizations are eligible to receive grants, not individuals or medical practice groups.
- The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.

II. Requirements

Date RFP Issued

- May 31, 2023

Clinical Area

- Allergic, Inflammatory, and Immune Skin Diseases

General Area of Interest for this RFP:

Projects that will be considered for Pfizer support will focus on the improvement of quality of care for patients with allergy, inflammatory, and immune skin diseases.

For the treatment of allergy, inflammation, and immune skin diseases, some issues have been pointed out such as the knowledge gap among healthcare professionals²⁾ and unequal accessibility of medical care³⁾. Important means of addressing these issues include constructing cooperative networks among the disease-specialized and non-specialized facilities, training specialists and medical staff in disease treatment, and coordinating with different departments involved in medical care³⁾⁴⁾.

Through this project, we aim to support educational programs designed for systematic and continuous actions that lead to measurable improvement in healthcare services and the health status of the patients, in these means, which will lead to the possible provision of more appropriate medical care to patients with the diseases.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Target Audience

- The interest of this grant opportunity is to support educational programs for all healthcare professionals involved in the etiology, diagnosis, treatment, and management of the Allergic, Inflammatory, and Immune Skin Diseases.

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to 2,500,000 JPY will be considered.

Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

Key Dates:

- RFP release date: 5/31/2023
- Grant Application due date: ~~7/31/2023~~ **Extended Due Date: 8/16/2023**
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: 10/31/2023
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: 1/1/2024 to 12/31/2026

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled

- Please go to www.cybergrants.com/pfizer/QI and sign in. First-time users should click “Create your password”. [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]
- Click the “Start a New Quality Improvement Application” button.
- In the application:
 - For the question “Competitive Grant?” select Yes
 - Select the following Competitive Grant Program Name: *2023 I&I JP: Approaches to Improve Delivery of Quality of Care for Patients with I&I Skin Diseases*
- Select the following Primary Area of Interest: *Inflammation and Immunology - General*
- Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see Appendix) in the Full Proposal Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

- MEG-J Office, Pfizer Japan Inc.
meg.japan@pfizer.com
- Please include the title of this open call, “Approaches to Improve Delivery of Quality of Care for Patients with Inflammatory, and Immune Skin Diseases” in the subject line of your e-mail.

Please click [here](#) to view Frequently Asked Questions regarding the Competitive Grant Program

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.
- Payment will only be made to requesting Institution.

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

References

- (1) 10-year strategic outlook toward 20390: Japan's research for allergy and immunology (December 2018, discussed on Review Committee for Japan's research for allergy and immunology"
- (2) Ogawa and Okuyama, Treatment of Psoriasis with Biologics in Cooperation with Regional Medical Institutions, J Environ Dermatol Cutan Allergol 11(4), 289-295, 2017
- (3) Basic guideline for allergy disease control (March 21, 2017, Ministry of Health, Labor and welfare, Notification No.76)
- (4) Advancement of utilizing information technology in the areas of health and medical care (Ministry of Health, Labor and welfare)

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Appendix

Quality Improvement Project Full Proposal

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Full Proposal documents should be no longer than 10-15 pages in length (12-point font and 1-inch margins) excluding Organization Detail and References. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s).
- List the overall objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project.

Assessment of Need for the Project

- Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.

Target Audience

- Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population

Project Design and Methods

- Describe the planned project and the way it addresses the established need.
- If your methods include educational activities, please describe succinctly the topic(s) and format of those activities

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed.
- Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data.
- Quantify the amount of change expected from this project in terms of your target audience.
- Describe how the project outcomes will be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- **[Include only if RFP begins with an LOI stage]** A total amount requested is the only information needed for the LOI stage. Full Budget is not required. This amount can be adjusted at the Full Proposal stage as applicable.
- The budget amount requested must be in U.S. dollars (USD). **[Revise accordingly if local currency will be used.]**
- While estimating your budget please keep the following items in mind:
 - General organizational running costs such as insurances, heating, lighting, rent, building maintenance may be included. Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
 - The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
 - It should be noted that grants awarded through GMG cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.